Mark Munch Sells 7,000 Shares of Bruker (NASDAQ:BRKR) Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 7,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. The trade was a 5.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bruker Trading Down 4.7%

Bruker stock traded down $2.53 during midday trading on Tuesday, hitting $50.88. 4,868,403 shares of the stock were exchanged, compared to its average volume of 2,847,863. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. The stock’s 50-day simple moving average is $46.43 and its 200 day simple moving average is $39.81. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $63.95. The stock has a market capitalization of $7.73 billion, a price-to-earnings ratio of -318.00, a PEG ratio of 7.02 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio is -125.00%.

Analysts Set New Price Targets

Several analysts recently issued reports on BRKR shares. Redburn Partners set a $60.00 price objective on shares of Bruker in a report on Thursday, November 20th. Rothschild Redb raised shares of Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a report on Wednesday, December 10th. TD Cowen increased their price objective on shares of Bruker from $42.00 to $53.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Finally, Rothschild & Co Redburn assumed coverage on Bruker in a research report on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $52.29.

Institutional Investors Weigh In On Bruker

A number of hedge funds have recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd acquired a new position in shares of Bruker in the second quarter worth $192,735,000. AQR Capital Management LLC boosted its holdings in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP grew its stake in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Brown Advisory Inc. increased its holdings in Bruker by 13.9% during the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.